



CIN No. : L24239DL2004PLC125888

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/57

February 6, 2025

**To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051**

**To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai - 400 001**

Symbol: AKUMS

Scrip Code: 544222

Sub: Press Release

Respected Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



Akums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and 15% Adj PAT growth

New Delhi, February 6, 2025: Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, 2024, delivering 12% increase in Adjusted EBITDA on year on year basis.

Key Highlights:

Quarter ended December 31, 2024	9 months ended December 31, 2024
<ul style="list-style-type: none"> Adj EBITDA Margin at 13.3% Adj PAT Margin at 6.5% Adjusted EBITDA of Rs 1,359 million up 12.1% YoY up 0.9% QoQ Total Income at Rs 10,250 million decline of 6.1% YoY decline of 2.1% QoQ Adjusted PAT of Rs 663 million up 15.2% YoY decline of 0.5% QoQ <p>Segmental</p> <ul style="list-style-type: none"> CDMO EBITDA of Rs 1,214 million up 9.2% YoY down 1.1% QoQ Branded and Generic EBITDA of Rs 198 million down 17.1% YoY up 9.9% QoQ API EBITDA at Rs -109 million 	<ul style="list-style-type: none"> Adj EBITDA Margin at 13.0% Adj PAT Margin at 6.1% Adjusted EBITDA of Rs 4,013 million down 3.6% YoY Total Income at Rs 30,972 million Reduction of 4.9% YoY Adjusted PAT of Rs 1,903 million up 9% YoY <p>Segmental</p> <ul style="list-style-type: none"> CDMO EBITDA margin Rs 3,652 million robust at 15.4% Branded and Generic EBITDA margin Rs 549 million at 10.5% API EBITDA at Rs -373 million

For Q3, Operating performance of the company was robust with overall Adj EBITDA growing 12% YoY and Adj PAT growing 15% YoY driven by better profitability in our core CDMO segment. The EBITDA improvement shows our continued improvement in the product mix. API EBITDA losses reduced significantly in Q3 YoY, although prices of cephalosporin APIs still remain low. Additionally, branded formulation business continues to perform well across domestic and export markets.

Sanjeev Jain, Managing Director, also shared his views, stating, “Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a €200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.”

Sandeep Jain, Managing Director, stated, “We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.”

Financial Performance

Particulars (Rs Mn)	Q3 FY 25	Q2 FY 25	Q3 FY 24	9m FY 25	9m FY 24
Total Income	10,250	10,466	10,918	30,972	32,578
Adj EBITDA	1,359	1,347	1,212	4,013	4,163
Adj EBITDA Margin	13.3%	12.9%	11.1%	13.0%	12.8%
Adj PAT	663	667	575	1,903	1,745
Adj PAT Margin	6.5%	6.4%	5.3%	6.1%	5.4%

For more information, contact:

Mr. Ankit Jain

Email: ankit.jain@akums.net

Disclaimer

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Akums Drugs and Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Definitions

- Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter/period, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items.
- Segment EBITDA is calculated as the sum of profit before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense pertaining to respective segment.
- Adjusted PAT is calculated as the profit for the quarter/period plus fair value changes to financial instruments less tax impact on account of business merger.
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients

Details of Earnings Call:

- **Date:** Friday, February 7th, 2024
- **Time:** 4:00 pm (IST)
- **Dial-In Numbers:**
 - Universal Access: +91 22 6280 1144 / +91 22 7115 8045
 - USA: 1 866 746 2133
 - UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448